NDAORALGRANULEPriority Review
Approved
Sep 2017
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
4/8 — Partial
Priority Review
SOLOSEC (secnidazole) by Evofem Biosciences. Approved for diverticulitis. First approved in 2017.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SOLOSEC (secnidazole) is an oral nitroimidazole antimicrobial approved in 2017 for the treatment of diverticulitis. It is administered as a single-dose granule formulation. The drug works through the nitroimidazole class mechanism to target bacterial infections in diverticulitis.
$70KPart D
Peak15.6 years to LOESOLOSEC is in peak lifecycle stage with minimal Part D penetration (217 claims in 2023), suggesting a small, specialized commercial footprint focused on specialty sales channels.
Mechanism of Action
Pharmacologic Class:
Nitroimidazole Antimicrobial
Worked on SOLOSEC at Evofem Biosciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.